DDrare: Database of Drug Development for Rare Diseases

37. 膿疱性乾癬（汎発型）
［臨床試験数：58，薬物数：50（DrugBank：18），標的遺伝子数：17，標的パスウェイ数：96］

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AIN457; AIN457, 150mg; ANAKINRA; ANB019; Acitretin; Adalimumab; Alefacept; Alvarez 2; Anakinra; Anti-IL-36R monoclonal antibody; BI 655130; BI655130; Brodalumab; Brodalumab 210mg SC; CNTO1959; Calcitriol; Certolizumab Pegol; Certolizumab pegol; Efalizumab; GUSELKUMAB; Guselkumab; Guselkumab 100 mg; Infliximab; Infliximab [infliximab biosimilar 3]; Ixekizumab; KHK4827; KHK4827 140mg SC; KHK4827 210mg SC; LY3074828; MONOCLONAL ANTIBODY ANTI-IGG1; Mirikizumab; Null; P32; P32/98; P32/98 3%; Placebo; Raptiva; Risankizumab; SECUKINUMAB; Secukinumab; Secukinumab 150 mg/1 mL Solution for injection; Secukinumab 150mg; Secukinumab 300mg; Silikis 3µg/g Salbe; Spesolimab; TA-650; TG; TREMFYA®; Tremfya; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04183881 (ClinicalTrials.gov)	July 4, 2016	29/11/2019	A Phase 4 Clinical Study of Brodalumab	An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma	Psoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic Erythroderma	Drug: Brodalumab 210mg SC	Kyowa Kirin Co., Ltd.	NULL	Completed	18 Years	N/A	All	138	Phase 4	Japan
2	JPRN-JapicCTI-142430	01/2/2014		A Phase 3 Clinical Study of KHK4827	An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma	Psoriasis	Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : Subcutaneous administration Control intervention name : null	Kyowa Hakko Kirin Co., Ltd.	NULL		18		BOTH	165	Phase 3	NULL
3	JPRN-JapicCTI-132057	01/2/2013		An open-label, non-controlled study of KHK4827 in subjects with psoriasis	A Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythroderma	Psoriasis	Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : Subcutaneous administration Control intervention name : null	Kyowa Hakko Kirin Co., Ltd.	NULL		18		BOTH		Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04183881
(ClinicalTrials.gov)

July 4, 2016

29/11/2019

A Phase 4 Clinical Study of Brodalumab

An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma

Psoriasis Vulgaris;Psoriatic Arthritis;Pustular; Psoriasis, Palmaris Et Plantaris;Psoriatic Erythroderma

Drug: Brodalumab 210mg SC

Kyowa Kirin Co., Ltd.

NULL

Completed

18 Years

N/A

All

138

Phase 4

Japan

JPRN-JapicCTI-142430

01/2/2014

A Phase 3 Clinical Study of KHK4827

An Extension Study of KHK4827 Subjects with Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma

Psoriasis

Intervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null

Kyowa Hakko Kirin Co., Ltd.

NULL

BOTH

165

Phase 3

NULL

JPRN-JapicCTI-132057

01/2/2013

An open-label, non-controlled study of KHK4827 in subjects with psoriasis

A Long-Term Study of KHK4827 in Subjects with Pustular Psoriasis (Generalized) and Psoriatic Erythroderma

Psoriasis

Intervention name : KHK4827
INN of the intervention : brodalumab
Dosage And administration of the intervention : Subcutaneous administration
Control intervention name : null

Kyowa Hakko Kirin Co., Ltd.

NULL

BOTH

Phase 3

NULL